PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26585822-0 2015 Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer. Platinum 51-59 AKT serine/threonine kinase 1 Homo sapiens 31-34 26585822-2 2015 The PI3K/Akt pathway plays a role in chemoresistance to platinum-based neoadjuvant chemotherapy (NAC). Platinum 56-64 AKT serine/threonine kinase 1 Homo sapiens 9-12 26585822-3 2015 The objective of this study was to evaluate the association between genetic polymorphisms in the PI3K/Akt pathway and chemotherapeutic outcomes following platinum-based NAC in Northwestern Chinese Han patients with squamous cervical cancer (SCC). Platinum 154-162 AKT serine/threonine kinase 1 Homo sapiens 102-105 26585822-12 2015 SIGNIFICANCE: The findings from this study demonstrate that genetic polymorphisms in the PI3K/Akt pathway are associated with sensitivity to platinum-based chemotherapy in SCC patients. Platinum 141-149 AKT serine/threonine kinase 1 Homo sapiens 94-97 26497682-1 2015 Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Platinum 78-86 AKT serine/threonine kinase 1 Homo sapiens 43-46 26497682-1 2015 Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Platinum 78-86 AKT serine/threonine kinase 1 Homo sapiens 196-199 26497682-8 2015 Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum. Platinum 137-145 AKT serine/threonine kinase 1 Homo sapiens 98-101 26497682-8 2015 Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum. Platinum 174-182 AKT serine/threonine kinase 1 Homo sapiens 98-101 25115278-3 2015 Recently high level of AKT was shown to be involved in platinum resistance and furthermore in resistance against Natural-killer (NK)-cell mediated killing in ovarian cancer. Platinum 55-63 AKT serine/threonine kinase 1 Homo sapiens 23-26 26579492-6 2015 DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a core component of NHEJ and it has shown considerable promise as a chemosensitization target in numerous cancer types, including ovarian cancer where it functions to promote platinum-induced survival signaling, via AKT activation. Platinum 236-244 AKT serine/threonine kinase 1 Homo sapiens 277-280 25462204-12 2015 CONCLUSION: These data suggest that brown algae phlorotannins may improve the efficacy of platinum drugs for ovarian cancer by enhancing cancer cell apoptosis via the ROS/Akt/NFkappaB pathway and reduce nephrotoxicity by protecting against normal kidney cell damage. Platinum 90-98 AKT serine/threonine kinase 1 Homo sapiens 171-174 26675567-8 2015 In particular, we focus on the mechanism of platinum resistance in clear cell carcinoma, including the role of annexin A4, one of the most investigated factors of platinum resistance, as well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1beta, ZNF217. Platinum 44-52 AKT serine/threonine kinase 1 Homo sapiens 258-261 26039708-0 2015 Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. Platinum 126-134 AKT serine/threonine kinase 1 Homo sapiens 56-59 25519148-12 2015 IMPLICATIONS: AKT-targeted therapy has value in a first-line setting as well as a second-line treatment for recurrent disease developing after platinum-based chemotherapy or bevacizumab treatment. Platinum 143-151 AKT serine/threonine kinase 1 Homo sapiens 14-17 23877012-7 2013 RESULTS: Phospho-AKT (serine473) expression correlated with survival from OVCA (P<0.05) and platinum-response (P=0.004). Platinum 95-103 AKT serine/threonine kinase 1 Homo sapiens 17-20 25281495-12 2014 CONCLUSIONS: We established that amplifications in 14q32.33 were associated with reduced OS, PFS, PFI and platinum resistance in three independent cohorts, suggesting that AKT1 amplifications act as a potentially predictive marker for EOC treated with platinum-based chemotherapy. Platinum 106-114 AKT serine/threonine kinase 1 Homo sapiens 172-176 25281495-12 2014 CONCLUSIONS: We established that amplifications in 14q32.33 were associated with reduced OS, PFS, PFI and platinum resistance in three independent cohorts, suggesting that AKT1 amplifications act as a potentially predictive marker for EOC treated with platinum-based chemotherapy. Platinum 252-260 AKT serine/threonine kinase 1 Homo sapiens 172-176 23408298-1 2013 BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy. Platinum 240-248 AKT serine/threonine kinase 1 Homo sapiens 67-70 22322152-9 2012 Studies of mechanism revealed that E Platinum suppressed activation of mTOR and p70S6K by decreasing phosphorylation of Akt, ERK1/2, JNK and p38 involved in mitogen-activated protein kinase signaling. Platinum 37-45 AKT serine/threonine kinase 1 Homo sapiens 120-123 22484552-3 2012 RESULTS: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p <= 0.006, n = 6 per group). Platinum 48-56 AKT serine/threonine kinase 1 Homo sapiens 13-16 22484552-7 2012 CONCLUSIONS: Therapeutic inhibition of AKT activation in acquired platinum-resistant disease can be imaged noninvasively by [(18)F]FDG-PET and [(18)F]FLT-PET warranting further assessment. Platinum 66-74 AKT serine/threonine kinase 1 Homo sapiens 39-42 22992944-0 2012 Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Platinum 31-39 AKT serine/threonine kinase 1 Homo sapiens 18-21 22992944-7 2012 AKT overexpression (confirmed by western blotting) converted platinum-sensitive A2780 into platinum-resistant cells as shown by MTT assay. Platinum 73-81 AKT serine/threonine kinase 1 Homo sapiens 0-3 22992944-7 2012 AKT overexpression (confirmed by western blotting) converted platinum-sensitive A2780 into platinum-resistant cells as shown by MTT assay. Platinum 103-111 AKT serine/threonine kinase 1 Homo sapiens 0-3 22992944-8 2012 Importantly, platinum resistance of A2780cis cells could be reversed by downregulation of AKT, as demonstrated by MTT and clonogenicity assays and FACS analysis. Platinum 13-21 AKT serine/threonine kinase 1 Homo sapiens 102-105 22901187-0 2012 Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Platinum 59-67 AKT serine/threonine kinase 1 Homo sapiens 34-37 22901187-7 2012 CONCLUSIONS: Our findings suggest that genetic variants in the PI3K/PTEN/AKT/mTOR pathway may predict platinum-based chemotherapy response in advanced NSCLC patients in a Chinese population. Platinum 102-110 AKT serine/threonine kinase 1 Homo sapiens 73-76 22131882-0 2011 DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Platinum 79-87 AKT serine/threonine kinase 1 Homo sapiens 16-19 22131882-5 2011 The AKT pathway is central to cell survival and has been implicated in platinum resistance. Platinum 71-79 AKT serine/threonine kinase 1 Homo sapiens 4-7 22131882-6 2011 Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells. Platinum 19-27 AKT serine/threonine kinase 1 Homo sapiens 48-51 22131882-6 2011 Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells. Platinum 110-118 AKT serine/threonine kinase 1 Homo sapiens 48-51 22131882-6 2011 Here, we show that platinum exposure induces an AKT-dependent, prosurvival, DNA damage response in clinically platinum-resistant but not platinum-sensitive cells. Platinum 110-118 AKT serine/threonine kinase 1 Homo sapiens 48-51 22131882-8 2011 Inhibition of DNA-PK or AKT, but not mTORC2, restores platinum sensitivity in a panel of clinically resistant HGS ovarian cancer cell lines: we also demonstrate these effects in other tumor types. Platinum 54-62 AKT serine/threonine kinase 1 Homo sapiens 24-27 21057220-11 2011 Our results indicate that the Akt, but not necessarily EGFR, is one of the most important target in the response of the platinum-based chemotherapy and prognosis for ovarian cancer patients. Platinum 120-128 AKT serine/threonine kinase 1 Homo sapiens 30-33 20405296-0 2011 Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Platinum 118-126 AKT serine/threonine kinase 1 Homo sapiens 52-55 20032415-0 2009 The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Platinum 30-38 AKT serine/threonine kinase 1 Homo sapiens 4-7 20447721-0 2011 PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Platinum 121-129 AKT serine/threonine kinase 1 Homo sapiens 10-13 30364051-0 2018 Toxicological Implications of Platinum Nanoparticle Exposure: Stimulation of Intracellular Stress, Inflammatory Response, and Akt Signaling In Vitro. Platinum 30-38 AKT serine/threonine kinase 1 Homo sapiens 126-129 15501963-2 2004 In cell lines derived from human non-small cell lung cancers (NSCLCs), Akt has been shown to confer chemoresistance by inhibition of apoptosis in response to different chemotherapeutic agents including platinum-based agents, which are often the first-line therapy for NSCLCs. Platinum 202-210 AKT serine/threonine kinase 1 Homo sapiens 71-74 34365218-4 2021 Utilizing improved PIP3-AKT and ERK1/2 activation Bioluminescence Resonance Energy Transfer (BRET) sensors, we report chemotherapy-induced ERK1/2 activation predominantly in cisplatin-paclitaxel resistant EOC cells and increased activation of both ERK1/2 and AKT in malignant ascites derived cancer cells from platinum-resistant patients but not from treatment-naive or platinum-sensitive relapse patients. Platinum 310-318 AKT serine/threonine kinase 1 Homo sapiens 259-262 34717622-17 2021 The immunohistochemical staining results showed that p-FLNC, AKT1 and p-ERK1/2 were highly expressed in platinum-resistant clinical specimens but weakly expressed in platinum-sensitive specimens, and platinum-resistant osteosarcoma specimens demonstrated weak expression of p-JNK. Platinum 104-112 AKT serine/threonine kinase 1 Homo sapiens 61-65 34681173-8 2021 Mild antagonism was observed in combination with platinum- or taxane-based chemotherapy, which was putatively related to treatment-induced activation of p38, JNK1/2, ERK1/2, MEK1/2, and AKT, functioning as potential pro-survival factors. Platinum 49-57 AKT serine/threonine kinase 1 Homo sapiens 186-189 33827148-0 2021 Role of FOXO protein"s abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer. Platinum 71-79 AKT serine/threonine kinase 1 Homo sapiens 56-59 33669671-5 2021 However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition. Platinum 209-217 AKT serine/threonine kinase 1 Homo sapiens 144-147 32703189-17 2020 Additionally, we show that PT-induced apoptosis was mediated by activating p38 MAPK and inhibiting AKT pathways. Platinum 27-29 AKT serine/threonine kinase 1 Homo sapiens 99-102 32642416-6 2020 In addition, Pt-CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity. Platinum 13-15 AKT serine/threonine kinase 1 Homo sapiens 39-42 35093146-9 2022 Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance. Platinum 120-128 AKT serine/threonine kinase 1 Homo sapiens 229-232 35093146-9 2022 Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance. Platinum 120-128 AKT serine/threonine kinase 1 Homo sapiens 239-242 35093146-9 2022 Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance. Platinum 143-151 AKT serine/threonine kinase 1 Homo sapiens 229-232 35093146-9 2022 Further Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis indicated the Differentially expressed genes (DEGs) in platinum-resistant and platinum-sensitive patients were mainly enriched in the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway and focal adhesion pathway, which are associated with platinum resistance. Platinum 143-151 AKT serine/threonine kinase 1 Homo sapiens 239-242 32934772-8 2020 pS or pT treatment of SCC xenografts increased apoptotic cell death and decreased pro-survival P-Akt (S473) and Survivin, demonstrating the effectiveness of the peptides in vivo. Platinum 6-8 AKT serine/threonine kinase 1 Homo sapiens 97-100 32083163-5 2020 Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss. Platinum 79-87 AKT serine/threonine kinase 1 Homo sapiens 54-57 29262602-0 2017 Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway. Platinum 43-51 AKT serine/threonine kinase 1 Homo sapiens 68-71 29910616-6 2018 In addition, treatment with Au@Pt-NSs led to upregulation of phospho-p38 MAPK and downregulation of phospho-AKT in EJ cells. Platinum 31-33 AKT serine/threonine kinase 1 Homo sapiens 108-111 28139737-6 2017 These results establish a novel mechanism by which NF-kappaB and Akt contribute to chemoresistance involving a signaling pathway consisting of histone H4, DNA-PK, RIP1 and IAPs that attenuates ROS-mediated apoptosis, and targeting this pathway may improve the anticancer efficacy of platinum-based chemotherapy. Platinum 283-291 AKT serine/threonine kinase 1 Homo sapiens 65-68 28342452-3 2017 Polymorphisms in genes involved in DNA repair and others such as PI3K/PTEN/AKT and TGF-beta pathways have been demonstrated to be associated with response, survival and toxicity in advanced NSCLC patients treated with platinum-based chemotherapy. Platinum 218-226 AKT serine/threonine kinase 1 Homo sapiens 75-78 27517495-2 2016 However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear.Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells. Platinum 131-139 AKT serine/threonine kinase 1 Homo sapiens 329-332 27677586-8 2016 We apply TDJGL to the PI3K/AKT/mTOR pathway in ovarian tumors to build differential networks associated with platinum resistance. Platinum 109-117 AKT serine/threonine kinase 1 Homo sapiens 27-30 27196780-5 2016 Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins. Platinum 0-8 AKT serine/threonine kinase 1 Homo sapiens 81-84 27196780-8 2016 We conclude that mTORC1/2 inhibition is superior to mTORC1 inhibition in reversing platinum resistance in tumors and strongly impairs AKT activation, DNA repair responses, and translation, promoting improved survival in the background of platinum resistance. Platinum 238-246 AKT serine/threonine kinase 1 Homo sapiens 134-137